CL2019002566A1 - Anticuerpos anti-phf-tau y usos de estos. - Google Patents

Anticuerpos anti-phf-tau y usos de estos.

Info

Publication number
CL2019002566A1
CL2019002566A1 CL2019002566A CL2019002566A CL2019002566A1 CL 2019002566 A1 CL2019002566 A1 CL 2019002566A1 CL 2019002566 A CL2019002566 A CL 2019002566A CL 2019002566 A CL2019002566 A CL 2019002566A CL 2019002566 A1 CL2019002566 A1 CL 2019002566A1
Authority
CL
Chile
Prior art keywords
antibodies
phf
tau antibodies
tau
tauopathies
Prior art date
Application number
CL2019002566A
Other languages
English (en)
Inventor
Marc Mercken
Thomas Malia
Marianne Borgers
Kolen Kristof Van
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2019002566A1 publication Critical patent/CL2019002566A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN ANTICUERPOS MONOCLONALES ANTI-PHF-TAU Y FRAGMENTOS DE UNIÓN AL ANTÍGENO DE ESTOS. ADEMÁS, SE DESCRIBEN ÁCIDOS NUCLEICOS QUE CODIFICAN LOS ANTICUERPOS, COMPOSICIONES QUE COMPRENDEN LOS ANTICUERPOS, MÉTODOS PARA PRODUCIR LOS ANTICUERPOS Y USAR LOS ANTICUERPOS PARA TRATAR O PREVENIR AFECCIONES, TALES COMO TAUOPATÍAS.
CL2019002566A 2017-03-16 2019-09-09 Anticuerpos anti-phf-tau y usos de estos. CL2019002566A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16

Publications (1)

Publication Number Publication Date
CL2019002566A1 true CL2019002566A1 (es) 2019-12-27

Family

ID=63521020

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002566A CL2019002566A1 (es) 2017-03-16 2019-09-09 Anticuerpos anti-phf-tau y usos de estos.

Country Status (21)

Country Link
US (3) US10766953B2 (es)
EP (1) EP3596119A4 (es)
JP (2) JP7159185B2 (es)
KR (2) KR20230155025A (es)
CN (2) CN110799531B (es)
AR (1) AR111288A1 (es)
AU (1) AU2018234709A1 (es)
BR (3) BR122023021958A2 (es)
CA (1) CA3055598A1 (es)
CL (1) CL2019002566A1 (es)
EA (1) EA201992038A1 (es)
IL (2) IL310464A (es)
JO (1) JOP20180021A1 (es)
MA (1) MA47789A (es)
MX (1) MX2019010922A (es)
PH (1) PH12019501973A1 (es)
SG (1) SG11201907754RA (es)
TW (1) TWI771389B (es)
UY (1) UY37635A (es)
WO (1) WO2018170351A1 (es)
ZA (1) ZA202101318B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6674888B2 (ja) 2013-03-13 2020-04-01 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
FI3452507T3 (fi) 2016-05-02 2022-12-15 Tau-immuunihoito
EA201892417A1 (ru) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед Антитела, распознающие тау
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
CN110881274A (zh) 2017-05-02 2020-03-13 普罗塞纳生物科学有限公司 识别tau的抗体
JP6851549B2 (ja) 2017-10-16 2021-03-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗タウ抗体及びその使用
BR112021016947A2 (pt) 2019-03-03 2021-11-03 Prothena Biosciences Ltd Anticorpos que reconhecem tau
CA3140201A1 (en) * 2019-05-31 2020-12-03 Xiyun CHAI Compounds and methods targeting human tau
CA3148740A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
CR20220505A (es) * 2020-04-08 2023-05-31 Janssen Biotech Inc Anticuerpos anti-phf-tau y usos de estos
WO2022013286A1 (en) * 2020-07-14 2022-01-20 Janssen Pharmaceutica Nv Blood-based assay for detecting tauopathy or amyloidogenic disease
CA3199806A1 (en) * 2020-10-26 2022-05-05 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
TW202231661A (zh) * 2020-10-26 2022-08-16 比利時商健生藥品公司 安全投予抗ｔａｕ抗體之方法
AU2022222134A1 (en) * 2021-02-19 2023-07-13 Eisai R&D Management Co., Ltd. Anti-pt217 tau antibody
WO2022201123A1 (en) 2021-03-26 2022-09-29 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (zh) * 2022-04-28 2023-11-07 厦门大学 针对p-tau 217的抗体及其用途
CN116948024B (zh) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 抗Tau蛋白的捕获抗体
CN116948023B (zh) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau蛋白抗体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
JP3909084B2 (ja) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
ATE335007T1 (de) * 1993-12-21 2006-08-15 Innogenetics Nv Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
WO1996004309A1 (en) 1994-07-29 1996-02-15 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
WO2004067568A2 (en) 2003-01-24 2004-08-12 Applied Molecular Evolution, Inc Human il-1 beta antagonists
CA2548817A1 (en) 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP1720908A2 (en) * 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
ES2452067T3 (es) 2006-08-04 2014-03-31 Novartis Ag Anticuerpo específico para EPHB3 y usos del mismo
JP2010235447A (ja) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
JP2013508287A (ja) 2009-10-14 2013-03-07 ヤンセン バイオテツク，インコーポレーテツド 抗体を親和性成熟する方法
ES2566602T3 (es) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anticuerpos anti-ErbB3
MY164376A (en) 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
EA031698B1 (ru) * 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Человеческие анти-тау антитела
AU2012359039B2 (en) 2011-12-20 2017-08-24 Janssen Biotech, Inc. Anti-PHF-tau antibodies and their uses

Also Published As

Publication number Publication date
US20230047413A1 (en) 2023-02-16
TWI771389B (zh) 2022-07-21
JP7159185B2 (ja) 2022-10-24
US20210179696A1 (en) 2021-06-17
KR20190130133A (ko) 2019-11-21
IL310464A (en) 2024-03-01
UY37635A (es) 2018-09-28
BR122023021947A2 (pt) 2024-02-20
US11365244B2 (en) 2022-06-21
US20180265575A1 (en) 2018-09-20
CN117209599A (zh) 2023-12-12
WO2018170351A8 (en) 2019-12-19
EA201992038A1 (ru) 2020-02-06
AR111288A1 (es) 2019-06-26
KR102597462B1 (ko) 2023-11-03
TW201900682A (zh) 2019-01-01
US10766953B2 (en) 2020-09-08
EP3596119A1 (en) 2020-01-22
WO2018170351A1 (en) 2018-09-20
KR20230155025A (ko) 2023-11-09
IL268700A (en) 2019-10-31
SG11201907754RA (en) 2019-09-27
CA3055598A1 (en) 2018-09-20
CN110799531B (zh) 2023-08-04
MX2019010922A (es) 2019-11-08
JP2022191383A (ja) 2022-12-27
EP3596119A4 (en) 2021-01-13
JP2020513804A (ja) 2020-05-21
PH12019501973A1 (en) 2020-06-29
JOP20180021A1 (ar) 2019-01-30
ZA202101318B (en) 2023-03-29
IL268700B1 (en) 2024-03-01
CN110799531A (zh) 2020-02-14
BR122023021958A2 (pt) 2024-02-20
MA47789A (fr) 2020-01-22
AU2018234709A1 (en) 2019-08-29
BR112019019049A2 (pt) 2020-04-22

Similar Documents

Publication Publication Date Title
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
ECSP20082991A (es) Agentes aglutinantes del psma y usos de estos
ECSP18041833A (es) Anticuerpos que se unen específicamente a pd-1 y sus usos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO2018000211A2 (es) Moléculas de anticuerpo que se unen a cd45
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
MX2018003936A (es) Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones.
CR20170079A (es) Agentes de unión a cd123 y usos de estos
AR093394A1 (es) Anticuerpos especificos del factor de crecimiento b derivado de plaquetas (pdgf-b), composiciones y usos de estos
CO2018012513A2 (es) Anticuerpos
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
AR108975A1 (es) Anticuerpos con baja inmunogenicidad y sus usos
ECSP22078815A (es) Anticuerpos anti-phf-tau y usos de estos
ECSP17080733A (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
EA201890434A1 (ru) Антитела к cd154 и способы их применения
CL2021001615A1 (es) Anticuerpos anti il-36 y procedimientos de uso de estos
UY39699A (es) Anticuerpos anti-tau y usos de estos
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
EA202092122A1 (ru) Антитела против tip-1 и их применения
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.